<DOC>
	<DOC>NCT03036150</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Provision of signed informed consent prior to any study specific procedures Female or male aged ≥18 years at the time of consent eGFR ≥25 and ≤75 mL/min/1.73m2 (CKDEPI Formula) UACR ≥200 and ≤5000 mg/g at visit 1 Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACEI or ARB for at least 4 weeks before visit 1, if not medically contraindicated, Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCAassociated vasculitis Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment History of organ transplantation Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor Type 1 diabetes mellitus New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Kidney Disease (CKD)</keyword>
	<keyword>Cardiovascular Events (CV)</keyword>
	<keyword>Phase III outcome trial</keyword>
</DOC>